Article Information
vol. 5 no. 3
Published By
Online ISSN
History
- Received January 9, 2019
- Accepted June 21, 2019
- Published online September 25, 2019.
Copyright & Usage
Copyright ©ERS 2019 http://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Andrew Menzies-Gow1⇑,
- Jonathan Corren2,3,
- Elisabeth H. Bel4,
- Jorge Maspero5,
- Liam G. Heaney6,
- Mark Gurnell7,
- Peter Wessman8,
- Ubaldo J. Martin9,
- Shahid Siddiqui9 and
- Esther Garcia Gil10
- 1Royal Brompton Hospital, London, UK
- 2Depts of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- 3Allergy Medical Clinic, Los Angeles, CA, USA
- 4Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
- 5Fudación CIDEA, Buenos Aires, Argentina
- 6Queen's University Belfast, Belfast, UK
- 7Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- 8AstraZeneca, Gothenburg, Sweden
- 9AstraZeneca, Gaithersburg, MD, USA
- 10AstraZeneca, Barcelona, Spain
- Andrew Menzies-Gow, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK. E-mail: a.menzies-gow{at}rbht.nhs.uk
Funding
AstraZeneca
Article usage
Altmetrics
Vol 5 Issue 3
Table of Contents
Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
